Teicoplanin is a glycopeptide antibiotic commonly used to treat Gram-positive bacterial infections in the clinic. The aim of this study was to provide a therapeutic reference for the clinical application and dosage regimen adjustment of teicoplanin by identifying factors associated with its plasma trough concentration (C trough ). A retrospective study was performed on patients with suspected or documented Gram-positive infections who were hospitalized from November 2017 to January 2020 and treated with teicoplanin while undergoing routine therapeutic drug monitoring (TDM). A total of 112 C trough trough measurements were obtained from 72 patients were included in this study. SPSS software was used for correlation analysis and receiver operator characteristic curve (ROC) analysis. The C trough for teicoplanin showed statistically significant relationships (P<0.05) with PLT, S cr , CL cr , eGFR, BUN and Cys-C. ROC curve analysis revealed that CL cr and eGFR were more sensitive and specific for C trough compared to the other factors. These findings should be considered in the clinical application of teicoplanin and for its dosage adjustment.